Cleveland Clinic: Adults Stopping GLP-1 Medications Regain Most Weight
Adults stopping semaglutide or tirzepatide regain nearly three-quarters of their lost weight, according to data released on Saturday at the ObesityWeek conference in National Harbor.
Key Clinical Takeaways:
- Patients discontinuing semaglutide regain an average of 73.7 percent of lost weight, while those stopping tirzepatide regain 69.2 percent.
- Continuous medication keeps patients at a 10.9 percent weight reduction, whereas treatment cessation leaves only a 3.9 percent net loss after two years.
A per-protocol analysis of electronic health records from the Cleveland Clinic tracked 20,486 adults with type-2 diabetes or obesity between 2021 and 2025. Patients who continued their baseline GLP-1 receptor agonist achieved a body weight reduction of 10.9 percent after two years, while those who stopped the medication retained a reduction of only 3.9 percent.
| Intervention Strategy | Two-Year Weight Reduction |
|---|---|
| Bariatric Surgery | 26.6 percent |
| Medication Switch (Semaglutide to Tirzepatide) | 16.0 percent |
| Continuous Baseline Medication | 10.9 percent |
| Medication Switch to Alternative Agent | 8.1 percent |
| Treatment Discontinuation | 3.9 percent |
Phenomix Sciences analyzed records for 45,017 adults to measure weight trajectory following the end of pharmacotherapy. While active treatment reduced body weight by 11.3 percent with semaglutide and 11.0 percent with tirzepatide, cessation triggered rapid regain. Patients recovered half of their lost weight within six months for semaglutide and within five months for tirzepatide.
High-risk groups regained half their lost weight in 1.8 to 2.0 months, whereas low-risk groups maintained their reduction for 19.0 to 19.2 months before reaching the same threshold.
Data from the Understanding America Study show that 33.4 percent of treated individuals discontinued their medication within two years. The drop-out rate reached 41 percent for obesity indications compared to 22 percent for diabetes.
Gastrointestinal side effects such as vomiting and monthly out-of-pocket costs starting at 51 US dollars drove the cessation rates higher. Gallup National Health and Well-Being Index figures indicate that U.S. adult usage of GLP-1 drugs for weight loss rose from 3 percent in 2024 to 11 percent in 2026, with 15 percent reporting past use.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.